𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Randomized, Controlled, Clinical Study of Thymosin Alpha-1 Versus Interferon-Alpha in Chinese Patients with Chronic Hepatitis B Lacking Hepatitis B Envelope Antigen

✍ Scribed by Jing You; Hong-Ying Cheng; Shou-Ming Yan; Yan-Wei Qiao; Jun-Hua Huang; Bao-Zhang Tang; Guo-Bing Wu; Jun-Yan Qu; Rong-Xue Wu; Lin Zhuang; Yong-Liang Ma

Book ID
118653761
Publisher
Elsevier Science
Year
2005
Tongue
Chinese
Weight
123 KB
Volume
68
Category
Article
ISSN
1726-4901

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-Ξ±1 versus interferon alfa treatment in patients with hepatitis B e antigen antibodyβ€”and hepatitis B virus DNAβ€”positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 187 KB πŸ‘ 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

A randomized controlled trial of lymphob
A randomized controlled trial of lymphoblastoid interferon-Ξ± in patients with chronic hepatitis B lacking HBeAg
✍ Giovanna Fattovich; Patrizia Farci; Massimo Rugge; Lucio Brollo; Antonella Manda πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 641 KB

Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoi

Efficacy of thymosin Ξ±1 in patients with
Efficacy of thymosin Ξ±1 in patients with chronic hepatitis B: A randomized, controlled trial
✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 107 KB πŸ‘ 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T